Skip to content
Screener

Monte Rosa Therapeutics, Inc. GLUE Other Income (Expense)

Other Income (Expense) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$61M+112%
Arvinas logo
ArvinasARVN
$6.3M-46.2%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$14.4M+81.2%
Vor Biopharma logo
Vor BiopharmaVOR
-$184.43M-23,010%
Biohaven logo
BiohavenBHVN
$168K-65.9%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$778K+13.2%

Other financials

Income statement

See full
Revenue$9.0M-61.3%
Operating income-$49.1M-216%
Net income-$43.4M-253%
EPS (diluted)-$0.43-187%

Balance sheet

See full
Cash & equivalents$90.1M+29.8%
Total debt$38.0M-7.6%
Total equity$487.3M+81.8%
Total assets$691.2M+92.2%

Cash flow

See full
Operating cash flow-$44.1M-27.1%
CapEx$4.7M+179%
Free cash flow-$48.8M-34.1%

Valuation

See full
Market cap$1.33B+395%
Enterprise value$1.28B+432%
P/S46.2×+44.7×

Profitability

See full
Operating margin-633%
Net margin-560.8%
FCF margin-111.7%-125pp

Returns & leverage

See full
Return on equity-42.7%
Debt / equity0.1×-0.1×
Current ratio10.6×+3.4×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:09 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336711
(in thousands, except share and per share amounts)Three months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Interest income5,9163,06811,5076,507
Foreign currency exchange gain251,390171,563
Gain on disposal of property and equipment59
Total other income5,9414,45811,5248,129
Net (loss) income before income taxes(43,189)(11,096)(87,640)36,611
Income tax provision(208)(1,199)(260)(2,021)
Net (loss) income$(43,397)$(12,295)$(87,900)$34,590
Comprehensive (loss) income:

Item 1. Financial Statements

FAQ

What is Monte Rosa Therapeutics, Inc.'s other income (expense)?
Monte Rosa Therapeutics, Inc. (GLUE) reported other income (expense) of $5.94M in Q2 2026.
How has Monte Rosa Therapeutics, Inc.'s other income (expense) changed year-over-year?
Monte Rosa Therapeutics, Inc.'s other income (expense) increased by 33.3% year-over-year, from $4.46M to $5.94M.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s other income (expense)?
Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s other income (expense) has grown at a 91.5% compound annual growth rate (CAGR), from -$1.08M to $14.49M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Monte Rosa Therapeutics, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude